Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
Francisco-Javier PeñalverJosé-Antonio MárquezSoledad DuránPilar GiraldoAlejandro MartínCarlos MontalbánJuan-Manuel SanchoMaría-José RamírezMaría-José TerolFrancisco-Javier CapoteAntonio GutierrezBlanca SánchezAndrés LópezAntonio Salar-SilvestreGil Rodríguez-CaravacaMiguel CanalesMaría-Dolores Caballeronull nullPublished in: Cancer medicine (2019)
ClinicalTrials.gov # NCT01133158.